Literature DB >> 23895073

Current trends in aortic valve replacement: development of the rapid deployment EDWARDS INTUITY valve system.

Michael A Borger1, Pascal Dohmen, Martin Misfeld, Friedrich W Mohr.   

Abstract

Although conventional aortic valve replacement (AVR) surgery remains the gold standard for patients with aortic stenosis, transcutaneous aortic valve replacement is becoming increasingly common in high-risk patients. The techniques of minimal invasive surgery (MIS) have been well known for many years, but MIS is applied in a disappointingly low percentage of patients undergoing AVR surgery. The EDWARDS INTUITY rapid deployment aortic valve system is designed to facilitate the performance of MIS AVR surgery. In addition, the reduced implantation times may be beneficial in higher risk patients or those requiring concomitant procedures. The system combines established pericardial valve technology with modern stent expertise obtained from the transcutaneous aortic valve replacement experience. Preliminary results from a multicenter trial have shown low rates of morbidity and mortality, and excellent hemodynamic performance. The EDWARDS INTUITY promises to be an exciting device that may further change the landscape of aortic valve intervention.

Entities:  

Mesh:

Year:  2013        PMID: 23895073     DOI: 10.1586/17434440.2013.811828

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  10 in total

Review 1.  Transcatheter Aortic Valve Implantation (TAVI): Is it Time for This Intervention to be Applied in a Lower Risk Population?

Authors:  Ioannis M Panayiotides; Evagoras Nikolaides
Journal:  Clin Med Insights Cardiol       Date:  2014-11-13

Review 2.  Current Clinical Evidence on Rapid Deployment Aortic Valve Replacement: Sutureless Aortic Bioprostheses.

Authors:  Glenn R Barnhart; Malakh Lal Shrestha
Journal:  Innovations (Phila)       Date:  2016 Jan-Feb

3.  Sutureless Aortic Valve Replacement in a Patient with Transfemoral Aortic Valve Replacement and Left Ventricular Hypertrophy.

Authors:  Torsten Christ; Pascal M Dohmen; Michael Laule; Karl Stangl; Wolfgang Konertz
Journal:  Thorac Cardiovasc Surg Rep       Date:  2015-07-10

4.  Are Sutureless Aortic Valves Suitable for Severe High-Risk Patients Suffering from Active Infective Aortic Valve Endocarditis?

Authors:  Alexander Weymann; Johanna Konertz; Michael Laule; Karl Stangl; Pascal M Dohmen
Journal:  Med Sci Monit       Date:  2017-06-08

5.  Introduction of the Rapid Deployment Aortic Valve System Use in Elderly Patients With Endocarditis.

Authors:  Alper Öner; Christoph Hemmer; Anthony Alozie; Benjamin Löser; Pascal M Dohmen
Journal:  Front Cardiovasc Med       Date:  2022-03-22

6.  Sutureless aortic valve replacement in high-risk patients with active infective endocarditis.

Authors:  Alina Zubarevich; Arian Arjomandi Rad; Marcin Szczechowicz; Arjang Ruhparwar; Alexander Weymann
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

7.  Valve-in-Valve Replacement Using a Sutureless Aortic Valve.

Authors:  Pascal M Dohmen; Lukas Lehmkuhl; Michael A Borger; Martin Misfeld; Friedrich W Mohr
Journal:  Am J Case Rep       Date:  2016-10-03

8.  Rapid Deployment Aortic Valves Deliver Superior Hemodynamic Performance In Vitro.

Authors:  Lisong Ai; Harvey Chen; Virginia Lin; Vinayak N Bapat
Journal:  Innovations (Phila)       Date:  2017 Sep/Oct

9.  Benefits of rapid deployment aortic valve replacement with a mini upper sternotomy.

Authors:  Siobhan Chien; Callum Clark; Saumya Maheshwari; Charilaos-Panagiotis Koutsogiannidis; Vipin Zamvar; Vincenzo Giordano; Kelvin Lim; Renzo Pessotto
Journal:  J Cardiothorac Surg       Date:  2020-08-26       Impact factor: 1.637

10.  The Aortic Annulus Stabilization Technique Prevents Paravalvular Leaks after Rapid Deployment Aortic Valve Implantation.

Authors:  Elena Caporali; Roberto Lorusso; Tiziano Torre; Francesca Toto; Alberto Pozzoli; Giovanni Pedrazzini; Stefanos Demertzis; Enrico Ferrari
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.